HomeBiotechnologyADMA Biologics Pronounces Closing of $69 Million Public Providing Together with Full...

ADMA Biologics Pronounces Closing of $69 Million Public Providing Together with Full Train of Underwriters’ Choice to Buy Extra Shares

Final Up to date on December 9, 2022 by GlobeNewsWire

RAMSEY, N.J. and BOCA RATON, Fla., Dec. 09, 2022 (GLOBE NEWSWIRE) — ADMA Biologics, Inc. (Nasdaq:ADMA) (“ADMA” or the “Firm”), an end-to-end industrial biopharmaceutical firm devoted to manufacturing, advertising and creating specialty plasma-derived biologics, at this time introduced the closing of its beforehand introduced underwritten public providing of 20,979,020 shares of its widespread inventory at a public providing worth of $2.86 per share, along with the train in filled with the underwriters’ choice to buy an extra 3,146,853 shares of widespread inventory. The gross proceeds from the train of the overallotment choice had been $9 million, bringing the whole gross proceeds to ADMA from the providing to $69 million, earlier than deducting underwriting reductions and commissions and different estimated providing bills.

ADMA intends to make use of the online proceeds from this providing to speed up commercialization and manufacturing actions, full plasma middle buildout and procure FDA approvals, to conclude publish FDA advertising approval analysis and improvement initiatives, and for working capital, capital expenditures and for normal company functions.

Raymond James & Associates, Inc., Cantor Fitzgerald & Co. and Mizuho Securities USA LLC acted as joint book-running managers of the providing.

The providing of the securities described above was made by the Firm pursuant to a “shelf” registration assertion on Kind S-3 (File No. 333-256643) beforehand filed with the Securities and Change Fee (“SEC”) and declared efficient by the SEC on August 3, 2021. The ultimate prospectus complement, together with the accompanying prospectus, referring to the providing was filed with the SEC on December 7, 2022 and is obtainable on the SEC’s web site at http://www.sec.gov. Digital copies of the ultimate prospectus complement and the accompanying prospectus referring to the providing could also be obtained from Raymond James & Associates, Inc., Consideration: Fairness Syndicate, 880 Carillon Parkway, St. Petersburg, Florida 33716, or by phone at (800) 248-8863, or e-mail at prospectus@raymondjames.com, or from Cantor Fitzgerald & Co., Attn: Capital Markets, 499 Park Avenue, 4th Ground, New York, New York 10022 or by e mail at prospectus@cantor.com, or from Mizuho Securities USA LLC, Consideration: Fairness Capital Markets, 1271 Avenue of the Americas, third Ground, New York, NY 10020, by e mail at US-ECM@us.mizuho-sc.com, or by phone at (212) 205-7600.

This press launch shall not represent a suggestion to promote or the solicitation of a suggestion to purchase any securities described herein, nor shall there be any sale of those securities in any state or jurisdiction by which such supply, solicitation or sale can be illegal previous to registration or qualification beneath the securities legal guidelines of any such state or jurisdiction.

About ADMA Biologics, Inc. (ADMA)

ADMA Biologics is an end-to-end industrial biopharmaceutical firm devoted to manufacturing, advertising and creating specialty plasma-derived biologics for the remedy of immunodeficient sufferers in danger for an infection and others in danger for sure infectious illnesses. ADMA presently manufactures and markets three United States Meals and Drug Administration (FDA)-approved plasma-derived biologics for the remedy of immune deficiencies and the prevention of sure infectious illnesses: BIVIGAM(R) (immune globulin intravenous, human) for the remedy of main humoral immunodeficiency (PI); ASCENIV(TM) (immune globulin intravenous, human – slra 10% liquid) for the remedy of PI; and NABI-HB(R) (hepatitis B immune globulin, human) to offer enhanced immunity towards the hepatitis B virus. ADMA manufactures its immune globulin merchandise at its FDA-licensed plasma fractionation and purification facility positioned in Boca Raton, Florida. Via its ADMA BioCenters subsidiary, ADMA additionally operates as an FDA-approved supply plasma collector within the U.S., which supplies a portion of its blood plasma for the manufacture of its merchandise. ADMA’s mission is to fabricate, market and develop specialty plasma-derived, human immune globulins focused to area of interest affected person populations for the remedy and prevention of sure infectious illnesses and administration of immune compromised affected person populations who are suffering from an underlying immune deficiency, or who could also be immune compromised for different medical causes. ADMA has acquired U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793 and 10,259,865 and European Patent No. 3375789, amongst others, associated to sure facets of its merchandise and product candidates. For extra data, please go to www.admabiologics.com.

Cautionary Word Relating to Ahead-Wanting Statements

This press launch incorporates “forward-looking statements” pursuant to the secure harbor provisions of the Non-public Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. (“we,” “our” or the “Firm”). Ahead-looking statements embrace, with out limitation, any assertion which will predict, forecast, point out, or indicate future outcomes, efficiency or achievements, and should include such phrases as “estimate,” “venture,” “intend,” “forecast,” “goal,” “anticipate,” “plan,” “planning,” “anticipate,” “consider,” “will,” “is probably going,” “will doubtless,” “ought to,” “may,” “would,” “could,” or, in every case, their unfavorable, or phrases or expressions of comparable that means. These forward-looking statements embrace statements about ADMA’s meant use of proceeds generated from the providing. Precise occasions or outcomes could differ materially from these described on this doc attributable to various necessary elements. Present and potential safety holders are cautioned that there additionally may be no assurance that the forward-looking statements included on this press launch will show to be correct. Besides to the extent required by relevant legal guidelines or guidelines, ADMA doesn’t undertake any obligation to replace any forward-looking statements or to announce revisions to any of the forward-looking statements. Ahead-looking statements are topic to many dangers, uncertainties and different elements that would trigger our precise outcomes, and the timing of sure occasions, to vary materially from any future outcomes expressed or implied by the forward-looking statements, together with, however not restricted to, the dangers and uncertainties described in our filings with the U.S. Securities and Change Fee, together with our most up-to-date studies on Kind 10-Okay, 10-Q and 8-Okay, and any amendments thereto.


Skyler BloomSenior Director, Company Technique and Enterprise Improvement michelle@argotpartners.com



Please enter your comment!
Please enter your name here

Most Popular

Recent Comments